Oventus Medical Limited (ASX:OVN) announces that it has completed a first tranche placement of approximately 18 million shares to institutional and sophisticated investors at an issue price of $0.36 per share to raise approximately $6.5 million.
Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation for the Gold Coast Investment Showcase (June 21st & 22nd 2017).
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that it will receive a milestone payment of US$1m from AGC for meeting the primary endpoints of its Phase 1 safety trial of Progenza in patients with knee osteoarthritis. The company reported on the positive results of the trial on 22 May 2017.
Oventus Medical Ltd (ASX:OVN) is pleased to announce it has entered into a world-wide distribution agreement with Hong Kong based Modern Dental Group (HKG:3600). This is in addition to the recent announcement of the co-manufacturing agreement between Oventus and Modern Dental.
Wilsons maintain a BUY rating and $1.66 price target. Anatara's recent stock underperformance has simply reflected a slow quarter for news in the lead-up to a significant inflection point in the 2H.
Oventus Medical Ltd (ASX:OVN) is pleased to announce that low pressure CPAP without a mask is one step closer. Results from the initial pilot study generated significant interest when presented at the American Academy of Dental Sleep Medicine in Boston on June 2nd 2017. The conference is the premier world forum for the latest developments in dental sleep medicine.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide investors with an update on recent progress.
